Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL
NCT05856851Phase 3Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of tissue-plasminogen activator in ischemic stroke (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Modified Rankin Scale score 0-1 at 90 days. Started Aug 2023; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05856851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856851.